media article on viralytics, page-17

my interpretation to the melanoma poster is CAVATAK is adhering to the tumour cell, initiating an immune response not only to the virus (CAVATAK) but also to the tumour cell which means there's a two pronged attack on the tumour cell. From the virus and the immune system.

Plus the added bonus that the virus is able to replicate and last for 4-5weeks in some patients. I don't think at this stage they could ask for more than that in the 'friend or foe' stakes. Definite reduction in tumour sizes too.